Clinical trial
Edotecarin in Treating Women With Locally Advanced or Metastatic Breast Cancer…
NCT00070031 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00070031 |
|---|---|
| Title | Edotecarin in Treating Women With Locally Advanced or Metastatic Breast Cancer That Has Not Responded to Chemotherapy |
| Official title | A Phase II Study of Intravenous Edotecarin (PHA-782615) in Patients With Anthracycline- and Taxane-Refractory or Chemoresistant Metastatic Breast Cancer |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | edotecarin |
| Start date | Jun 1, 2003 |
| Primary completion | Apr 1, 2006 |
| Completion | Dec 1, 2009 |
| First posted | Oct 7, 2003 |
| Last update posted | Dec 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: